Venkat Ramanan - 16 Oct 2023 Form 4 Insider Report for Turnstone Biologics Corp. (TSBX)

Reporting relationship: Chief Financial Officer
Issuer ticker: TSBX
Reported as of: 16 Oct 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 17 Oct 2023, 18:42:44 UTC
Prior SEC filing: 20 Jul 2023
Next SEC filing: 18 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ P. Joseph Campisi, Jr., Attorney-in-Fact

Key filing fact

Venkat Ramanan filed Form 4 for Turnstone Biologics Corp. (TSBX) on 17 Oct 2023.

Key facts

This page summarizes Venkat Ramanan's Form 4 filing for Turnstone Biologics Corp. (TSBX).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 17 Oct 2023, 18:42.

Change

Previous filing in this sequence was filed on 20 Jul 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

TSBX transaction Derivative

Employee Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +46,606
Change %
Price: $0.000000
Shares after: 46,606
Date: 16 Oct 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 46,606
Exercise price: $2.61
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

One fourth (1/4th) of the shares subject to the option award shall vest on October 12, 2024, and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date.